Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).

@article{Barlsi2011PemetrexedAC,
  title={Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).},
  author={Fabrice Barl{\'e}si and Radj Gervais and Herv{\'e} L{\'e}na and Jos{\'e} Hureaux and Henri B{\'e}rard and Dominique Paillotin and Susana Bota and Isabelle Monnet and Abdesslam Chajara and Gilles Robinet},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 11},
  pages={2466-70}
}
BACKGROUND Brain metastases (BM) occur in up to 40% of non-small-cell lung cancer (NSCLC) patients. This trial assessed the safety and efficacy of pemetrexed-cisplatin in this population. PATIENTS AND METHODS Chemonaive NSCLC patients with BM ineligible for (radio)surgery, performance status (PS) of 0 to 2, were eligible for up to six cycles of cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) every 3 weeks. Whole -brain radiotherapy was given in case of disease progression or at chemotherapy… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].

Gan to kagaku ryoho. Cancer & chemotherapy • 2009
View 3 Excerpts
Highly Influenced

: results from 2 phase I studies

A Brade, A Bezjak, R Macrae
2010

Similar Papers

Loading similar papers…